ArticleMedical science monitor : international medical journal of experimental and clinical research2017
MicroRNA-588 is downregulated and may have prognostic and functional roles in human breast cancer.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Engineered Exosomes Carrying miR-588 for Treatment of Triple Negative Breast Cancer Through Remodeling the Immunosuppressive Microenvironment.International journal of nanomedicine · 2024Article
- Inflammation and tumor microenvironment.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Review
- Article
- Hypoxia-associated prognostic markers and competing endogenous RNA coexpression networks in lung adenocarcinoma.Scientific reports · 2022Article
- LncRNA ZFAS1 regulates the proliferation, oxidative stress, fibrosis, and inflammation of high glucose-induced human mesangial cells via the miR-588/ROCK1 axis.Diabetology & metabolic syndrome · 2022Article
- miR‑497/MIR497HG inhibits glioma cell proliferation by targeting CCNE1 and the miR‑588/TUSC1 axis.Oncology reports · 2021Article
- Long non-coding RNA SNHG8 promotes autophagy as a ceRNA to upregulate ATG7 by sponging microRNA-588 in colorectal cancer.Oncology letters · 2021Article
- Downregulation of miR-588 is associated with tumor progression and unfavorable prognosis in patients with osteosarcoma.Experimental and therapeutic medicine · 2021Article
- Article
- Gene Expression Profiling of Tricarboxylic Acid Cycle and One Carbon Metabolism Related Genes for Prognostic Risk Signature of Colon Carcinoma.Frontiers in genetics · 2021Article
- Cytochrome b561 Serves as a Potential Prognostic Biomarker and Target for Breast Cancer.International journal of general medicine · 2021Article
- Article
- Effects of microRNA-195 on the Prognosis of Glioma Patients and the Proliferation and Apoptosis of Human Glioma Cells.Pathology oncology research : POR · 2020Article
- Improving Model Performance on the Stratification of Breast Cancer Patients by Integrating Multiscale Genomic Features.BioMed research international · 2020Article
- Prognostic role of microRNAs in breast cancer: A systematic review.Oncotarget · 2019Article
- Distinct Diagnostic and Prognostic Values of Kinesin Family Member Genes Expression in Patients with Breast Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- MicroRNA-588 regulates invasion, migration and epithelial-mesenchymal transition via targeting EIF5A2 pathway in gastric cancer.Cancer management and research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND We explored the expression pattern, prognostic potential, and functional role of microRNA-588 (miR-588) in human breast cancer (BC). MATERIAL AND METHODS The expression pattern of miR-588 was assessed by qPCR in BC cell lines and human BC carcinomas. The correlations between miR-588 and BC patients' clinicopathological characteristics, as well as BC patients' overall survival, were statistically assessed. In in vitro culture, MCF-7 and MDA-MB-231 cells were infected with lentivirus to overexpress endogenous miR-588. The subsequent effects of miR-588 upregulation on BC cell proliferation and cisplatin chemosensitivity were examined. RESULTS miR-588 was found to be significantly downregulated in both BC cell lines and carcinoma tissues of BC patients. Low expression of miR-588 was closely correlated with BC patients' poor prognosis of TNM stage, lymph node metastasis, and estrogen receptor status. In addition, patients with low miR-588-expressing carcinomas had much shorter overall survival. In MCF-7 and MDA-MB-231 cells, lentiviral infection induced significant miR-588 upregulation, and miR-588 upregulation had an anti-tumor effect in BC cells by significantly inhibiting cancer proliferation and increasing cisplatin chemosensitivity. CONCLUSIONS miR-588 is downregulated in BC and its aberrant expression is closely associated with patients' poor prognosis and overall survival, thus suggesting a biomarker role. miR-588 also has anti-tumor function in BC, making it a potential therapeutic target for BC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.